miR-7: An anti-cancer micro RNA

MiReven is a biopharmaceutical company focused on developing miR-7 as a cancer therapy.  The Company was formed in 2010 through an investment from the Medical Research Commercialisation Fund (MRCF). The Company’s published research shows that miR-7 can knock-out an essential growth receptor for cancer, known as the epidermal growth factor receptor (EGFR), as well as its associated signaling pathways that promote cancer development. EGFR is a major target for cancer therapy because it is often associated with disease progression, resistance to chemotherapy and radiation therapy.